Shah R, Rosso K, Nathanson DS. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014; 5: 283-98, CrossRef.

Kementerian Kesehatan RI. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/414/2018 tentang Pedoman Nasional Pelayanan Kedokteran Tata Taksana Kanker Payudara. Jakarta: Kementerian Kesehatan RI; 2018.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424, CrossRef.

Tsuprykov O, Chen X, Hocher CF, Skoblo R, Lianghong Yin, Hocher B. Why should we measure free 25(OH) vitamin D? J Steroid Biochem Mol Biol. 2018; 180: 87-104, CrossRef.

Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14: 342-57, CrossRef.

Martínez-Reza I, Díaz L, Barrera D, Segovia-Mendoza M, Pedraza-Sánchez S, Soca-Chafre G, et al. Calcitriol inhibits the proliferation of triple-negative breast cancer cells through a mechanism involving the proinflammatory cytokines IL-1β and TNF-α. J Immunol Res. 2019; 2019: 6384278, CrossRef.

Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL. Plasma vitamin D levels, menopause, and risk of breast cancer: Dose-response meta-analysis of prospective studies. Medicine (Baltimore). 2013; 92: 123-31, CrossRef.

Hossain S, Beydoun MA, Beydoun HA, Chen X, Zonderman AB, Wood RJ. Vitamin D and breast cancer: A systematic review and meta-analysis of observational studies. Clin Nutr ESPEN. 2019; 30: 170-84, CrossRef.

Atoum M, Alzoughool F. Vitamin D and breast cancer: latest evidence and future steps. Breast Cancer Basic Clin Res. 2017; 11: 1178223417749816, CrossRef.

Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, et al. Vitamin D status at breast cancer diagnosis: Correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. 2012; 33: 1319-26, CrossRef.

Thanasitthichai S, Chaiwerawattana A, Prasitthipayong A. Association of vitamin D level with clinicopathological features in breast cancer. Asian Pacific J Cancer Prev. 2015; 16: 4881-3, CrossRef.

Palmieri C, MacGregor T, Girgis S, Vigushin D. Serum 25‐hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol. 2006; 59: 1334-6, CrossRef.

Imtiaz S, Raza S, Muhammad A, Siddiqui N, Loya A. Vitamin D deficiency in newly diagnosed breast cancer patients. Indian J Endocrinol Metab. 2012; 16: 409-13, CrossRef.

Damayanti AY, Indarto D, Wasita B, Ardyanto TD. Indeks massa tubuh, asupan vitamin D, dan serum 25-hydroxyvitamin D pada pasien kanker payudara. J Gizi Klin Indones. 2017; 14: 56-63, CrossRef.

Alexanian A, Sorokin A. Cyclooxygenase 2: Protein-protein interactions and posttranslational modifications. Physiol Genomics. 2017; 49: 667-81, CrossRef.

Cordes T, Hoellen F, Dittmer C, Salehin D, Kümmel S. Correlation of prostaglandin metabolizing enzymes and serum PGE 2 levels with vitamin D receptor and serum 25 (OH)2 D3 levels in breast and ovarian cancer. Anticancer Res. 2012; 358: 351-7, PMID.

Jana D, Sarkar DK, Ganguly S. Role of cyclooxygenase 2 ( COX-2 ) in prognosis of breast cancer. Indian J Surg Oncol. 2014; 5: 59-65, CrossRef.

Gomez I, Foudi N, Longrois D, Norel X. The role of prostaglandin E 2 in human vascular inflammation. Prostaglandins Leukot Essent Fat Acids. 2013; 89: 55-63, CrossRef.

Yuan L, Jiang R, Yang Y, Ding S, Deng H. 1,25-Dihydroxyvitamin D 3 inhibits growth of the breast cancer cell line MCF-7 and downregulates cytochrome P4501B1 through the COX-2 / PGE2 pathway. Oncol Rep. 2012; 28: 2131-7, CrossRef.

Liu W, Zhang L, Xu HJ, Li Y, Hu CM, Yang JY, et al. The anti-inflammatory effects of vitamin D in tumorigenesis. Int J Mol Sci. 2018; 19: 2736, CrossRef.

Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018; 50: 20, CrossRef.

Thill M, Hoellen F, Becker S, Dittmer C, Fischer D, Kümmel S, et al. Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cells. Anticancer Res. 2012; 32: 367-72, PMID.

de Sousa Almeida-Filho B, De Luca Vespoli H, Pessoa EC, Machado M, Nahas-Neto J, Nahas EAP. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women. J Steroid Biochem Mol Biol. 2017; 174: 284-9, CrossRef.

Janbabai G, Shekarriz R, Hassanzadeh H, Aarabi M, Samaneh Borhani S. A survey on the relationship between serum 25-hydroxy vitamin D level and tumor characteristics in patients with breast cancer. Int J Hematol Stem Cell Res. 2016; 10: 30-6, PMID.

Sofi NY, Jain M, Kapil U, Seenu V, R L, Yadav CP, et al. Reproductive factors, nutritional status and serum 25(OH)D levels in women with breast cancer: A case control study. J Steroid Biochem Mol Biol. 2018; 175: 200-4, CrossRef.

Xu F, Li M, Zhang C, Cui J, Liu J, Li J. Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer : a meta- analysis. Oncotarget. 2017; 8: 6003-12, CrossRef.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology Breast Cancer. Pennsylvania: NCCN; 2019.

Shamsi U, Khan S, Azam I, Khan AH, Maqbool A, Hanif M, et al. A multicenter case control study of association of vitamin D with breast cancer among women in Karachi, Pakistan. PLoS One. 2020; 15: e0225402, CrossRef.

Estébanez N, Gómez-Acebo I, Palazuelos C, Llorca J, Dierssen-Sotos T. Vitamin D exposure and risk of breast cancer: a meta-analysis. Sci Rep. 2018; 8: 9039, CrossRef.

Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol. 2011; 51: 311-36, CrossRef.

Kochel TJ, Goloubeva OG, Fulton AM. Upregulation of cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) pathway member multiple drug resistance-associated protein 4 (MRP4) and downregulation of prostaglandin transporter (PGT) and 15-prostaglandin dehydrogenase (15-PGDH) in triple-negative breast. Breast Cancer Basic Clin Res. 2016; 10: 61-70, CrossRef.

Moris D, Kontos M, Spartalis E, Fentiman IS. The role of NSAIDs in breast cancer prevention and relapse: current evidence and future perspectives. Breast Care. 2016; 11: 339-44, CrossRef.

Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007; 9: 210, CrossRef.

Frasor J, Weaver AE, Pradhan M, Mehta K. Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17β-estradiol and proinflammatory cytokines. Endocrinology. 2008; 149: 6272-9, CrossRef.